In the context of PPARγ therapeutic targeting, glitazones such as rosiglitazone, pioglitazone, and ciglitazone, seem to embody potent treatment agents which successfully suppress inflammation in endometriosis, decrease both the mean explant wet weight and the size of ectopic uterine tissues and even endorse fertility. This evidence concerns the gene PPARG and endometriosis.